A copy of the presentation materials can be accessed on the “Publication” section of the Company’s website at www.bioatla.com once the presentations have concluded.

Details for the poster presentation: Title: TACTI-004: a double-blinded, randomized phase 3 trial in patients with advanced/metasttic non-small cell cancer receiving eftilagimod alfa (MHC class II ...

Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak ® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced two upcoming ...

Xentria, a clinical-stage biopharmaceutical company advancing therapies for rare and serious diseases, today announced the successful completion of enrollment in the therapeutic dose-ranging phase of ...

Topline data from Phase 3 EFZO-FIT™ study of efzofitimod in pulmonary sarcoidosis expected in the third quarter of 2025.

LTRN READ THE FULL LTRN RESEARCH REPORT Lantern Pharma, Inc (NASDAQ:LTRN) continues to enroll its HARMONIC trial for LP-300 ...

With the growth of the global Bitcoin ecosystem, conferences continue to serve as a way to bring together innovators, entrepreneurs, and newcomers to discuss, share, and present solutions and case ...

Forty years after his alleged involvement in the kidnapping, torture, and killing of a Drug Enforcement Administration ... at a Friday news conference. This included ordering the “kidnapping ...

The rising adoption of artificial intelligence in the pharmaceutical industry dominated discussions at a conference in India this week ... US-based Parexel said it was piloting an AI model to generate ...

--(BUSINESS WIRE)--Aptar Pharma, leader in respiratory drug delivery solutions ... An integrated Poster & Exhibition session will run throughout the 3-day conference, ensuring ample opportunity ...

Researchers, academicians, and industry experts are invited to submit original articles within the scope of the conference ... in drug development. Integration of PK modeling. Advances in PK/PD ...